Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-Analysis
- Design
- Meta-analysis · 23467 participants · Mixed outcome
- Match to healthy normal-weight adults aged 55–75
- Different population[Auto] Synthesis of studies conducted predominantly in people with obesity/overweight.
- Could weight loss explain it?
- Specifically tested12.4% weight loss. The paper is internally inconsistent: the abstract says 35%-55% of cardiovascular benefit was independent of weight loss, but the results section says 35%-45% was weight-loss-mediated. The paper does not show how these mediation figures were derived from the included trials, so they are not established.
- Study tier
- Study tier 2[Auto] Systematic review/meta-analysis of randomized trials (auto-provisional; heterogeneity and included-study quality not assessed).
- Assessment
- Version 4 · Checked against the source by AI · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
A review of 16 trials (23,467 adults without diabetes who had obesity, or overweight with a weight-related condition) found GLP-1 drugs lowered major cardiovascular events by about 20% (RR 0.80), with lower rates of stroke, heart attack and heart-failure hospital stays, and 12.4% more weight loss than placebo. One trial, SELECT, carried 77% of the weight in the main analysis, and most of the 22.4% of participants with established heart disease came from it. The review is rated critically low confidence (AMSTAR 2), and its figures on how much of the benefit is independent of weight loss are inconsistent within the paper and not established.
What the study reported
- Drugs
- Class unspecified
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- 68 weeks follow-up
- Adverse events
- Not extracted
- Limitations
- Not extracted
Who was studied
- Bmi min
- 27
- Obesity status
- obesity/overweight present (all or most)
- Diabetes status
- excluded (no diabetes)
- Cvd status
- 22.4% had established cardiovascular disease, mostly from SELECT
- Sample size
- 23467
Study quality details
- Study design
- Meta-analysis
- Sample size
- 23467
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- 68 weeks follow-up
- Outcome type
- mixed
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% confidence intervals (CIs
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
How far the review's own results can be trusted
This record is a systematic review, so it is appraised with AMSTAR 2, which rates how far the review's own pooled results can be trusted. It does not grade the trials inside the review; those are appraised one by one.
On this scale High is the best rating. The levels run High, Moderate, Low, Critically low: Critically low confidence in the review is the worst rating a review can receive, and means it should not be relied on for an accurate summary. That is the opposite direction to the risk-of-bias scale used for single trials, where High is the worst.
Critically low confidence in the review · AMSTAR 2 · AI: two passes agreed (item splits settled by owner ruling)
Why: 4 critical items fail: review methods set out in a protocol before the review began; list of excluded studies, with reasons; appropriate methods for combining results; risk of bias taken into account when interpreting the results.
What it is used for here: Used only to find trials. A review at this level does not supply a pooled result to any outcome in this collection; the trials it lists are appraised on their own.
| Item | Answer |
|---|---|
| 1 Research question and inclusion criteria include the PICO components | Yes |
| 2 · critical Review methods set out in a protocol before the review began | No — a critical flaw |
| 3 Choice of included study designs explained | No |
| 4 · critical Comprehensive literature search | Partial Yes |
| 5 Study selection done by two reviewers independently | Yes |
| 6 Data extraction done by two reviewers independently | No |
| 7 · critical List of excluded studies, with reasons | No — a critical flaw |
| 8 Included studies described in adequate detail | Partial Yes |
| 9 · critical Satisfactory technique for assessing risk of bias in the included studies | Partial Yes |
| 10 Funding of the included studies reported | No |
| 11 · critical Appropriate methods for combining results | No — a critical flaw |
| 12 Effect of risk of bias on the pooled results assessed | Yes |
| 13 · critical Risk of bias taken into account when interpreting the results | No — a critical flaw |
| 14 Differences between study results explained and discussed | No |
| 15 · critical Publication bias investigated and its likely impact discussed | Yes |
| 16 Review authors' conflicts of interest and funding reported | Yes |
Where the two reviewers differed: item 3 (choice of included study designs explained): one read Yes, the other No; settled at No by a recorded ruling; item 13 (risk of bias taken into account when interpreting the results): one read Yes, the other No; settled at No by a recorded ruling.
Two reviewers assessed the review independently against a written guide (AMSTAR 2 guide, version 1.2), from the full text and retrieved supplements, 2026-10-05.
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
The source, as retrieved
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardiovascular benefits in diabetic populations, yet evidence in non-diabetic obesity remains limited. We searched PubMed, Excerpta Medica database (Embase), Cochrane Controlled Register of Trials (CENTRAL), and Web of Science (January 2015-January 2025) for randomized controlled trials evaluating GLP-1 RAs in non-diabetic adults with obesity (BMI ≥30 kg/m²), with composite major adverse cardiovascular events (MACE) as the primary outcome using random-effects models with risk ratios (RRs) and 95% confidence intervals (CIs). Sixteen trials (23,467 participants, median 68 weeks follow-up) were included, demonstrating that GLP-1 RAs reduced MACE by 20% (RR 0.80, 95% CI 0.72-0.89), with strongest effects on stroke (RR 0.72), myocardial infarction (RR 0.84), and heart failure hospitalization (RR 0.82), alongside reductions in systolic blood pressure (4.2 mmHg), triglycerides (32 mg/dL), and high-sensitivity C-reactive protein (hsCRP) (38.6%), with 12.4% weight loss where mediation analyses showed 35%-55% of cardiovascular benefit was independent of weight reduction. GLP-1 RAs provide substantial cardiovascular protection in non-diabetic obesity through both weight loss-dependent and independent mechanisms, with acceptable safety profiles supporting their role in cardiovascular risk reduction.